After-Hours Gainers: VCYT, RIGL, NPCE, CDNA, And FBLG Post Notable Moves Following Q3 Results

Several healthcare and biotech companies posted strong after-hours gains driven by robust third-quarter earnings and upward revisions to their 2025 financial guidance. Veracyte Inc. surged 16.07% after reporting a 26% increase in Q3 net income and raising its full-year 2025 revenue and adjusted EBITDA margin outlook. Rigel Pharmaceuticals, Inc. jumped 23.33% as its Q3 net income more than doubled and it increased its 2025 revenue guidance. Additionally, NeuroPace, Inc. and CareDx, Inc. saw gains, with NeuroPace narrowing its net loss and CareDx achieving a GAAP net income turnaround while also raising its 2025 revenue and EBITDA expectations, signaling positive momentum within the sector.

Analysis

The healthcare and biotech sectors demonstrated significant after-hours strength, propelled by robust third-quarter earnings and upward revisions to full-year 2025 financial guidance. This positive market reaction, characterized by a strongly positive sentiment, reflects improved operational performance and optimistic outlooks from several key companies.

Veracyte Inc. (VCYT) saw a 16.07% surge, driven by a 26% year-over-year increase in Q3 net income to $19.1 million and a raised 2025 total revenue guidance to $506-$510 million, with adjusted EBITDA margins now expected to exceed 25%. Rigel Pharmaceuticals (RIGL) jumped 23.33% after its Q3 net income more than doubled to $27.9 million and its 2025 revenue guidance was increased to $285-$290 million, while reaffirming full-year positive net income.

NeuroPace Inc. (NPCE) also contributed to sector strength by narrowing its Q3 net loss to $3.5 million on 30% revenue growth. CareDx Inc. (CDNA) achieved a GAAP net income turnaround of $1.7 million and raised its 2025 revenue and adjusted EBITDA guidance, signaling strong fundamental improvements. The consistent upward revisions across multiple firms underscore a healthy underlying business environment.

Key Decisions for Investors

• Investors should prioritize companies demonstrating strong earnings beats and upward revisions to future guidance, particularly those with improving profitability metrics like adjusted EBITDA margins.
• Consider the sustainability of clinical development funding alongside positive net income for long-term growth potential, as exemplified by Rigel's strategy.
• Exercise caution with price movements not explicitly backed by new fundamental disclosures, such as FibroBiologics, and conduct thorough due diligence.